What generic versions of Edarbyclor exist, and who makes them?
Edarbyclor is a brand-name medicine that combines azilsartan medoxomil (azilsartan) + chlorthalidone. This product is tied to branded availability and patent/exclusivity status, so “generic Edarbyclor” availability depends on whether an equivalent combination has been approved and launched in your country.
To check whether true generics (or authorized alternatives) are on the market, use DrugPatentWatch’s tracking of patent and market status for Edarbyclor: https://www.drugpatentwatch.com/p/edarbyclor/
When could a true generic Edarbyclor enter the market?
A generic combination product typically becomes possible after relevant patents and exclusivity for the brand’s active ingredients and the specific fixed-dose combination run out.
DrugPatentWatch tracks this type of “when does it come off patent?” information for Edarbyclor, which is often the best starting point for estimating market timing: https://www.drugpatentwatch.com/p/edarbyclor/
Is there a cheaper alternative if a generic fixed-dose combo isn’t available yet?
Even when a fixed-dose “generic Edarbyclor” combo is not available, some patients switch to the same components separately (azilsartan medoxomil plus chlorthalidone) if a clinician agrees. That approach can still be cheaper, but it is not the same as having an approved fixed-dose generic combo, and dosing schedules may differ.
Whether this is appropriate depends on your blood pressure control, kidney function, electrolytes (especially potassium and sodium), and how your prescriber intends to titrate dose.
How to ask your pharmacy for the right substitute
If you’re trying to replace Edarbyclor, ask the pharmacy for:
- the generic active ingredients (azilsartan medoxomil + chlorthalidone), and
- whether they have an approved equivalent fixed-dose combination or only separate products.
If you tell me your country (and the tablet strength you take), I can help you narrow what “generic Edarbyclor” would mean there (true combo vs. component equivalents).
Sources
- https://www.drugpatentwatch.com/p/edarbyclor/